Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Hum Mutat. 2020 Oct;41(10):1705-1721. doi: 10.1002/humu.24074. Epub 2020 Jul 17.
It is possible to estimate the prior probability of pathogenicity for germline disease gene variants based on bioinformatic prediction of variant effect/s. However, routinely used approaches have likely led to the underestimation and underreporting of variants located outside donor and acceptor splice site motifs that affect messenger RNA (mRNA) processing. This review presents information about hereditary cancer gene germline variants, outside native splice sites, with experimentally validated splicing effects. We list 95 exonic variants that impact splicing regulatory elements (SREs) in BRCA1, BRCA2, MLH1, MSH2, MSH6, and PMS2. We utilized a pre-existing large-scale BRCA1 functional data set to map functional SREs, and assess the relative performance of different tools to predict effects of 283 variants on such elements. We also describe rare examples of intronic variants that impact branchpoint (BP) sites and create pseudoexons. We discuss the challenges in predicting variant effect on BP site usage and pseudoexonization, and suggest strategies to improve the bioinformatic prioritization of such variants for experimental validation. Importantly, our review and analysis highlights the value of considering impact of variants outside donor and acceptor motifs on mRNA splicing and disease causation.
可以根据变异效应的生物信息学预测来估计种系疾病基因变异的先验致病性。然而,常规使用的方法可能导致对影响信使 RNA(mRNA)处理的非供体和受体剪接位点模体的变异的低估和漏报。这篇综述介绍了具有实验验证的剪接效应的遗传性癌症基因种系变异体,位于天然剪接位点之外。我们列出了 95 个外显子变异体,这些变异体影响 BRCA1、BRCA2、MLH1、MSH2、MSH6 和 PMS2 中的剪接调节元件(SRE)。我们利用现有的大规模 BRCA1 功能数据集来映射功能 SRE,并评估不同工具预测 283 个变体对这些元件的影响的相对性能。我们还描述了影响分支点(BP)位点并创建假外显子的罕见内含子变异体的例子。我们讨论了预测 BP 位点使用和假外显子化对变异体效应的挑战,并提出了用于此类变体的实验验证的生物信息学优先级排序的策略。重要的是,我们的综述和分析强调了考虑供体和受体模体之外的变异对 mRNA 剪接和疾病发病机制的影响的价值。